Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of Autologous CD19-BCMA Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Autoimmune Diseases

NCT07361094 is registered in ClinicalTrials.gov with Beijing Boren Hospital as lead sponsor.

NCT NCT07361094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07361094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of Autologous CD19-BCMA Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Autoimmune Diseases
Lead sponsor
Beijing Boren Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
November 6, 2025
Completion date
June 30, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory autoimmune hemolytic anemia, relapsed/refractory idiopathic inflammatory myopathies, relapsed/refractory multiple sclerosis, relapsed/refractory sjögren's syndrome, relapsed/refractory systemic lupus erythematosus, relapsed/refractory systemic sclerosis